Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.

The Journal of antimicrobial chemotherapy - 1 Aug 2014

Malet Isabelle, Gimferrer Arriaga Laura, Artese Anna, Costa Giosuè, Parrotta Lucia, Alcaro Stefano, Delelis Olivier, Tmeizeh Ahmed, Katlama Christine, Valantin Marc-Antoine, Ceccherini-Silberstein Francesca, Calvez Vincent, Marcelin Anne-Geneviève

Abstract excerpt

OBJECTIVES: The possibility of replacing raltegravir or elvitegravir with dolutegravir in heavily treatment-experienced patients failing on raltegravir/elvitegravir has been evaluated in VIKING trials. All studied patients failed by the most common pathways, Y143, Q148 and N155, and dolutegravir demonstrated efficacy except for Q148 viruses. The aim of this study was to explore, in the same way, the behaviour of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heterocyclic Compounds, 3-Ring
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Oxazines

Share to Pyridones

Share to Pyrrolidinones

Share to Quinolones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 24710029
DOI: 10.1093/jac/dku095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.PMID 24710029Read ↗

G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistanceSemantic proximity Read ↗

Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV IntegraseSemantic proximity Read ↗

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapySemantic proximity Read ↗

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitorsSemantic proximity Read ↗

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.Semantic proximity Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

Evolution of HIV integrase resistance mutations.Semantic proximity Read ↗

Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.Semantic proximity Read ↗

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.Semantic proximity Read ↗

Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.